Signet Healthcare Partners (“Signet”) has announced the successful sale of its portfolio company, Paragonix Technologies (“Paragonix”), to global medical technology leader Getinge. Paragonix, renowned for its advancements in organ transplantation and preservation, marks a significant acquisition for Getinge, enhancing its transplant technology offerings.
Signet partnered with Paragonix in March 2023, leading a $25 million Series B investment that provided essential growth capital and strategic support. As Paragonix’s sole institutional investor, Signet played a crucial role in its development, including facilitating a key acquisition in 2023 that broadened the company’s services. Under the leadership of Dr. Lisa Anderson, Paragonix achieved impressive global expansion and innovation in organ transplant technologies, setting new standards for safety and efficacy.
Ashley Friedman, Managing Director of Signet and a Board Director at Paragonix, praised the collaboration, highlighting Dr. Anderson’s leadership and the company’s growth. He expressed confidence that Paragonix, now part of Getinge, will continue to advance transplant technology worldwide.
Dr. Lisa Anderson emphasized the importance of Signet’s support, noting that their expertise and network were instrumental in Paragonix’s success and subsequent acquisition. She expressed excitement about joining forces with Getinge to further expand their global impact.
This transaction is a notable achievement for Signet’s new investment fund, Signet Healthcare Partners Fund V (“Fund V”), which focuses on commercial-stage pharmaceutical and medical device investments.
About Signet Healthcare Partners
Signet Healthcare Partners is a prominent investor in growth-stage healthcare companies, specializing in pharmaceuticals and medical devices. With over 25 years of experience, Signet has raised over $600 million in capital and invested in more than 60 companies, working closely with its portfolio to drive value and growth.
